Astellas Pharma, Inc.’s Veozah (fezolinetant) for hot flashes caused by menopause got off to a slow commercial start, despite a high unmet need for nonhormonal treatment options for menopausal women. A new updated warning from the US Food and Drug Administration on a rare but serious risk of liver injury could further complicate the commercial ramp.
Key Takeaways
- An updated warning on risk of liver injury could pose commercial headwinds for Astellas’s Veozah for hot flashes.
The updated warning may put Veozah at a disadvantage to Bayer AG’s rival drug elinzanetant, which could potentially launch...
